Hoon Sang Lee
Chief Strategy Officer The RIGHT Foundation
Dr. Hoon Sang Lee is a medical doctor and a global health expert, and currently the Chief Strategy Officer (CSO) of the RIGHT Foundation (Research Investment for Global Health Technology Foundation) and an adjunct professor at Yonsei University School of Public Health in Korea. Dr. Lee is also a member of Health Sector Advisory Committee of KOICA and a founding member of the Board for Korea Society of Global Health. Previously, he has worked as a health adviser for KOICA (Korea International Cooperation Agency) for bilateral health projects in various countries of Africa and Asia. Prior to KOICA, Dr. Lee worked as a medical officer at Korea CDC, managing national hepatitis B and measles immunization programme, and was involved in North Korea health programme for immunization support. Dr. Lee studied Economics and Public Policy at University of Chicago, received MD and PhD from Yonsei University School of Medicine and received MPH from Johns Hopkins School of Public Health.
Seminars
- Outline a strategy for global health R&D with end-to-end approach
- Explore a commitment for global health access with focus on health equity for infectious disease in low- and middle-income countries (LMICs)
- Discuss the scope of R&D funding support and upcoming opportunities for global health R&D
With organizations such as the Korean Disease Control and Prevention Agency (KDCA), the Korean Ministry of Health, and The RIGHT Foundation, driving investment into next-generation mRNA technologies, collaboration between Korean and international stakeholders to achieve success has never been more critical. They will also be key to advancing regional manufacturing capabilities and ensuring equitable access to vaccines worldwide, particularly across low- and middle-income countries (LMICs).
Hear from vaccine experts as they shed light on strategies to overcome the next pandemic through RNA technology innovations including:
- How to develop key biopharma partnerships to achieve the impact on global vaccine equity?
- How to leverage best practices for mRNA vaccine R&D and local manufacturing in LMICs?
- Outlining current bottlenecks with scaling up to ensure regional capacity and global availability of mRNA vaccines
